Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yedid Elbez

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
BMC Genomics|June 7, 2006
An analysis of intra array repeats: the good, the bad and the non informativeYedid Elbez, Shlomit Farkash-Amar, Itamar Simon
Journal of the American College of Cardiology|August 23, 2014
Lack of negative interaction between use of β-blockers and statins on cardiovascular outcomes among patients with or at risk for atherothrombosisJérémie Abtan, Yedid Elbez, Deepak L Bhatt, et al.
Clinical and Experimental Rheumatology|November 27, 2019
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysisEvo Alemao, Roelien Postema, Yedid Elbez, et al.
BMC Rheumatology|April 14, 2022
Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE studyPatrick Durez, Rene Westhovens, Femke Baeke, et al.
European Heart Journal|August 31, 2018
The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patientsEmmanuelle Vidal-Petiot, Yedid Elbez, Thomas F Lüscher, et al.
International Journal of Cardiology|June 13, 2017
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysisAnubodh Varshney, Ph Gabriel Steg, Yedid Elbez, et al.
Rheumatology International|May 2, 2020
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritisPhilip J Mease, Iain B McInnes, Vibeke Strand, et al.
Clinical Rheumatology|July 14, 2019
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countriesRieke Alten, Eugen Feist, Hanns-Martin Lorenz, et al.
Clinical Cardiology|May 19, 2017
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic eventsAnthony A Bavry, Islam Y Elgendy, Yedid Elbez, et al.
Arthritis Research & Therapy|January 14, 2018
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world settingRieke Alten, Harald Burkhardt, Eugen Feist, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
BMC Genomics|June 7, 2006
An analysis of intra array repeats: the good, the bad and the non informativeYedid Elbez, Shlomit Farkash-Amar, Itamar Simon
Journal of the American College of Cardiology|August 23, 2014
Lack of negative interaction between use of β-blockers and statins on cardiovascular outcomes among patients with or at risk for atherothrombosisJérémie Abtan, Yedid Elbez, Deepak L Bhatt, et al.
Clinical and Experimental Rheumatology|November 27, 2019
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysisEvo Alemao, Roelien Postema, Yedid Elbez, et al.
BMC Rheumatology|April 14, 2022
Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE studyPatrick Durez, Rene Westhovens, Femke Baeke, et al.
European Heart Journal|August 31, 2018
The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patientsEmmanuelle Vidal-Petiot, Yedid Elbez, Thomas F Lüscher, et al.
International Journal of Cardiology|June 13, 2017
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysisAnubodh Varshney, Ph Gabriel Steg, Yedid Elbez, et al.
Rheumatology International|May 2, 2020
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritisPhilip J Mease, Iain B McInnes, Vibeke Strand, et al.
Clinical Rheumatology|July 14, 2019
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countriesRieke Alten, Eugen Feist, Hanns-Martin Lorenz, et al.
Clinical Cardiology|May 19, 2017
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic eventsAnthony A Bavry, Islam Y Elgendy, Yedid Elbez, et al.
Arthritis Research & Therapy|January 14, 2018
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world settingRieke Alten, Harald Burkhardt, Eugen Feist, et al.
Pageof 6